695 results about "Phospholipin" patented technology

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

The invention belongs to the field of enzymatic preparation of structural phospholipids, and particularly relates to a method for preparing phosphatidylserine through interfacial enzyme catalysis. A series of high-activity immobilized phospholipase are prepared by innovatively adopting bifunctional group modified hollow mesoporous silica microspheres as a carrier and adsorbing immobilized phospholipase D. The catalyst has the functions of a catalyst and an emulsifier, and a Pickering emulsion interfacial enzyme catalysis system can be efficiently constructed. In the system, the phosphatidylcholine and the serine are efficiently converted into the phosphatidylserine through a phosphatidyl transfer reaction, the conversion rate of the phosphatidylserine within 20 minutes can reach 85%-95%, and the catalytic efficiency reaches up to 372 mmol / (g.h). In addition, after the catalyst is recycled for 10 times, the conversion rate is still kept at 70.9%, and the catalyst shows excellent stability and reusability. The method has the remarkable advantages of being mild in reaction condition, high in catalytic efficiency, capable of being repeatedly used and the like, and a new technical approach is provided for industrial production of phosphatidylserine.

The invention relates to bionic skin barrier cream with a three-layer phospholipid structure and a preparation method of the bionic skin barrier cream, and belongs to the technical field of cosmetics, the bionic skin barrier cream comprises the following raw materials: lecithin, wax ester, triglyceride, composite ceramide, phytosterol oleate, squalane, an antioxidant, polyol, composite amino acid, pyrrolidone carboxylic acid, urea and arginine. A stabilizing agent, a treating agent and the balance of deionized water. The bionic skin barrier cream prepared by the invention has a three-layer phospholipid structure, and compared with a double-layer phospholipid structure in the market, the firmness and hydrophobicity of the double-layer structure are further improved by the added third-layer structure, so that the prepared bionic skin barrier cream has outstanding waterproof, sweat-resistant and light pollution-resistant effects; in addition, the wax ester, the triglyceride, the phytosterol oleate, the pyrrolidone carboxylic acid and the urea selected in the invention have a synergistic effect, and can generate excellent moisturizing and repairing effects and certain protection effects.

The invention belongs to the technical field of bionic nano-drugs, and particularly relates to a bionic vesicle preparation as well as a preparation method and application thereof. The bionic vesicle preparation disclosed by the invention is prepared from the following raw materials: mesenchymal stem cell outer vesicles, nintedanib and DSPE-PEG-HA (hyaluronic acid modified pegylated phospholipid); the nintedanib is loaded in the mesenchymal stem cell outer vesicle, and the DSPE-PEG-HA is coupled to the surface of the mesenchymal stem cell outer vesicle. The bionic vesicle preparation disclosed by the invention can be used for directly delivering a drug to a pulmonary fibrosis injury part through inhalation type drug delivery, and acting on a focus part at a higher local concentration, meanwhile, the exposure of the drug in whole-body circulation is remarkably reduced, the occurrence of side effects is reduced, and the specific targeting intervention and regulation on fibroblasts are realized.

The invention discloses a compound composition for improving sleep disorders, which is characterized by comprising the following components: an inhibitory neurotransmitter component, melatonin and a nano-lipid carrier, the nano-lipid carrier comprises phospholipid and cholesterol, the weight ratio of phospholipid to cholesterol is (1-6): 1, the weight ratio of phospholipid to cholesterol is (1-6): 1, and the weight ratio of melatonin to cholesterol is (1-6): 1. The inhibitory neurotransmitter component is wrapped in the nano-lipid carrier to form lipid nanoparticles, and the weight ratio of the inhibitory neurotransmitter component to the nano-lipid carrier is 1: (1-15). The compound composition can be prepared into a compound oral mucosa preparation, can be rapidly disintegrated when encountering saliva in the oral cavity, is good in patient compliance and small in side effect, all the components play a synergistic effect from different mechanisms through multiple target points, and the compound oral mucosa preparation can improve the sleep quality, prolong the sleep time and shorten the sleep latency; and patients with sleep disorders are helped to improve insomnia from the pathologic root.

The invention belongs to the technical field of biological medicine, and discloses a novel adjuvant recombinant herpes zoster vaccine and a preparation method thereof. The vaccine is composed of gE-gD protein and a liposome adjuvant, the liposome adjuvant is prepared by the following steps: co-dissolving 3D-MLA, phospholipid-containing components and steroid components in an organic solvent to form a film, hydrating and homogenizing with PBS, finally adding QS-21, and fixing the volume with PBS. According to the process, enhanced components are uniformly and stably anchored in a membrane phase micro-domain, and the particle structure is controllable. Under the same antigen dosage and detection caliber, the D28 GMC of the vaccine is obviously improved, and more sufficient and stronger primary humoral immune response is embodied.

The invention belongs to the technical field of liquid chromatography-mass spectrometry detection pretreatment, and particularly relates to a pretreatment method for liquid chromatography-tandem mass spectrometry analysis of pesticide and veterinary drug residues in serum, which comprises the following steps: (S1) carrying out heating reaction on Sc (III) salt, Cu (II) salt and 1H-pyrazole-4-formic acid (H2PyC) in a polar aprotic solvent, and cooling to obtain a green crystal, namely MOF-919; the chemical formula of the MOF-919 is [Sc < 3 > (mu3-O) (OH) < 3 >] [Cu3 (mu3-O) (mu-PyC) < 3 > (H2O) < 6 >] < 2 >; (S2) mixing the serum sample with an acetonitrile solution containing formic acid, carrying out ultrasonic treatment, vortex oscillation and centrifugation, taking supernate, and diluting the supernate with an aqueous solution containing formic acid to obtain a to-be-purified solution; and (S3) adding MOF-919 into the to-be-purified liquid, mixing, performing ultrasonic treatment, performing vortex oscillation, centrifuging, and taking supernate, thereby completing the pretreatment of the to-be-purified liquid. According to the method, the MOF-919 is used for adsorbing chemical pollutant residues in serum, especially phospholipids, so that the purpose of removing the chemical pollutant residues in blood is achieved. The method is simple and convenient to operate, small in organic solvent consumption and good in purification effect, and can be widely applied to residue analysis of chemical pollutants in serum.

The invention discloses a hair follicle targeting nano-liposome anti-hair loss and hair growth compound preparation. The compound preparation is prepared from the following raw materials in parts by mass: 70 to 85 parts of bionic liposome carrier and 15 to 30 parts of active ingredients, the bionic liposome carrier is prepared from 50 to 60 parts of egg yolk lecithin, 15 to 20 parts of pH sensitive phospholipid DOPE, 10 to 15 parts of cholesterol and 5 to 10 parts of mesenchymal stem cell exosome membrane protein; the active ingredients comprise 5 to 10 parts of minoxidil, 3 to 5 parts of caffeine, 0.5 to 1 part of miR-218-5p, 1 to 2 parts of biotin and 2 to 3 parts of quercetin; the average particle size of the nano-liposome formed by the bionic liposome carrier is 120-180nm, and the polydispersity index (PDI) is less than or equal to 0.15. The invention relates to the technical field of biological medicines, in particular to a hair follicle-targeted nano-liposome anti-hair loss and hair growth compound preparation, which has the following advantages due to the adoption of the technical scheme: accurate targeted delivery is realized, and the treatment safety and accuracy are improved; intelligent response release is achieved, and the local microenvironment of hair follicles is optimized; the multi-target synergistic effect breaks through the limitation of single treatment.

The invention discloses a lipophilic liposome containing polydeoxyribonucleotide as well as a preparation method and application of the lipophilic liposome. The lipophilic liposome comprises the following components in parts by weight: 0.001-3 parts of polydeoxyribonucleotide; 0.5 to 3 parts of phospholipid; 0.1-2 parts of a cationic emulsifier; 0.1-3 parts of an anionic emulsifier; 40 to 70 parts of polyol; the total amount is 100 parts. According to the invention, an emulsifier system formed by combining lecithin with anionic and cationic compound surfactants is adopted, so that the transdermal absorption of PDRN is facilitated. The lipophilic liposome containing polydeoxyribonucleotide prepared by the invention can effectively resist nuclease degradation, prolong the acting time of PDRN in skin, and improve the skin anti-aging and repairing effects of the liposome. The anti-aging effect of the active ingredients is improved, and the bioavailability of the active ingredients is improved. The cosmetic composition can be widely applied to cosmetic formulas of various dosage forms.

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.

The invention discloses a metal polyphenol nano material based on chlorogenic acid and a preparation method and application thereof.The preparation method comprises the steps that chlorogenic acid and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 are mixed and dissolved in an anhydrous tetrahydrofuran solvent, and a first mixed solution is prepared; adding a FeCl3 solution into the first mixed solution until a clear and transparent system is formed, so as to obtain a second mixed solution; and removing the anhydrous tetrahydrofuran solvent of the second mixed solution to obtain the metal polyphenol nano material (CA-Fe NPs) based on chlorogenic acid. The metal polyphenol nano material has excellent photothermal conversion performance, and can be applied to in-vitro antibiosis, antioxidation, anti-inflammation and wound healing promotion.

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

The invention relates to a composition with antioxidant and brightening effects and capable of delaying skin saccharification as well as a preparation method and application of the composition, and belongs to the field of cosmetics. The composition comprises an ormosia henryi bark extract, tetrahydrocurcumin, a mirabilis jalapa extracting solution, a surfactant, polyol, phospholipid and a solvent. The composition provided by the invention has good illumination stability and high-temperature stability, and the composition provided by the invention is high in bioavailability, and has good antioxidant and brightening effects and lipofuscin and RAGE level inhibition effects.

The invention provides a cobalt monatomic nano-enzyme system modified by phospholipid polyethylene glycol carboxyl. The cobalt monatomic nano-enzyme system comprises a cobalt monatomic nano-enzyme composite core and phospholipid polyethylene glycol carboxyl compounded on the surface of cobalt monatomic nano-enzyme, the cobalt monatomic nano-enzyme composite core comprises a cobalt monatomic nano-enzyme and ginsenoside loaded on the cobalt monatomic nano-enzyme. The invention also provides a bifidobacterium synergetic cobalt monatomic nano-enzyme system which is formed by combining cobalt monatomic nano-enzyme with ginsenoside Rb1 and further delivering the cobalt monatomic nano-enzyme and ginsenoside Rb1 through bifidobacterium bifidum for targeted therapy of enteritis. The combination of Co SA and Rb1 can enhance the anti-inflammatory efficacy by adjusting a key immune signal pathway, and bifidobacterium bifidum can ensure targeted delivery of microbiota and promote intestinal barrier repair. The synergistic three-component strategy integrating monatomic nano-enzyme antioxidation, natural drug immunoregulation and probiotic targeting is provided, and a promising treatment platform is provided for accurate intervention of IBD.

The invention relates to a serum liquid chromatography-tandem mass spectrometry pretreatment method, which comprises: (S1) mixing a serum sample and a formic acid-containing acetonitrile solution, carrying out ultrasonic treatment, vortex oscillation and centrifugation, taking the supernatant, and diluting with a formic acid-containing aqueous solution to obtain a liquid to be purified; (S2) mixing the to-be-purified liquid with PCN-777, performing ultrasonic treatment, vortex oscillation and centrifugation, and taking supernate to obtain to-be-detected liquid; the PCN-777 is a C24H23N3O16Zr3 phospholipid removal material, and the PCN-777 is a C24H23N3O16Zr3 phospholipid removal material, and the PCN-777 is a C24H23N3O16Zr3 phospholipid removal material. According to the present invention, the serum ultra-high performance liquid chromatography-tandem mass spectrometry pretreatment method is developed by using the known MOFs material PCN-777, such that different types of phospholipids in the serum can be specifically, rapidly and effectively removed, the efficient recovery and detection of pesticide and veterinary drugs can be achieved, and the interference of phospholipids can be avoided.

The invention relates to the technical field of biological medicines, in particular to an iRGD targeted and anti-fibrosis small molecule dual-modified exosome as well as a construction method and application thereof. The exosome utilizes the specific binding penetration enhancement effect of iRGD (the amino acid sequence is CRGDKGPDC) and a fibroblast high-expression integrin receptor, so that the enrichment efficiency of the exosome at a focus part is improved; the anti-fibrosis micromolecule Let-7a-5p can inhibit a TGF-beta signal channel by blocking Smad2 / 3 phosphorylation, and the anti-fibrosis micromolecule Let-7a-5p and the anti-fibrosis microRNA carried by the exosome generate a synergistic anti-fibrosis effect; the exosome phospholipid bilayer can also protect Let-7a-5p from enzymolysis and prolong the half-life period, and iRGD modification can reduce the non-targeted uptake rate. An animal model verifies that the double-modified exosome has a good skin fibrosis resisting effect, and side effects such as liver and kidney function damage are not found. The invention provides an effective and safe treatment scheme for resisting skin fibrosis.

Provided herein are lipid nanoparticles composition comprising a lipid component which comprises: (i) a first ionizable cationic lipid, (ii) a PEG-lipid, wherein the PEG-lipid comprises a PEG-Ceramide. Further provided are lipid nanoparticle compositions comprising a lipid component which comprises: (i) a first ionizable cationic lipid, (ii) a PEG-lipid, wherein the PEG-lipid comprises a PEG-Ceramide selected from: N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)5000]} (C8 PEG5000-Ceramide), N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}(C8 PEG2000-Ceramide), N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)750]} (C8 PEG750-Ceramide), N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)5000]} (C16 PEG5000-Ceramide), N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]} (C16 PEG200-Ceramide), and N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)750]} (C16 PEG750-Ceramide) (iii) a phospholipid, and (iv) a permanently cationic lipid, an anionic lipid, or a second ionizable cationic lipid separate from the first ionizable cationic lipid.

The invention discloses a preparation method and application of a photo-thermal biosensor for tumor cell quantification and vitality dual-index liquid biopsy. Phosphatidylserine (PS) is exposed by enriching and cracking tumor cells, is identified and combined by an aptamer Apt2, and is driven to be separated from Apt2-Cu2-xTe NSs; after magnetic separation, separated supernatant is subjected to photo-thermal detection; the photo-thermal signal intensity is positively correlated with the number of cells, so that quantitative detection is realized; during cell apoptosis, PS is turned out of the membrane, Apt2-Cu2-xTe NSs is combined with the surface of the membrane, separated supernatant is subjected to photo-thermal detection after magnetic separation, and the photo-thermal signal enhancement amplitude is in negative correlation with cell activity. The platform has the advantages of POCT characteristics, low cost and portability, and a new tool is provided for precise tumor diagnosis and treatment.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The invention discloses a phospholipase A1 mutant and application thereof. According to the invention, PLA1 is modified to obtain a PLA1 mutant, compared with wild PLA1, the PLA1 mutant has the advantages that the optimum temperature is kept unchanged, the PLA1 mutant has higher phospholipase A1 activity at 40-50 DEG C, the optimum pH is changed from 3 to 8, and the PLA1 mutant keeps high phospholipase activity at the pH of 3-9 and is higher than the phospholipase activity of the PLA1 wild type under the optimum condition; the pH (Potential of Hydrogen) adaptability range of the PLA1 is widened. Therefore, the PLA1 mutant disclosed by the invention has a better application prospect, better meets the requirement on enzyme performance in phospholipid processing, can be used for degumming grease and producing lysophosphatide, and is applied to the fields of biology, food, medicine, beauty, agriculture, industry and the like.

The invention relates to the technical field of functional food and biological medicine, in particular to a modified pseudo-ginseng exosome and an intestinal conditioning gel composition and application thereof. According to the gel beverage, an exosome derived from panax notoginseng callus cultured in a laboratory is used as a core active component, is modified through phosphatidylserine-aminated pectin-genipin and is embedded into a hydrogel matrix composed of carboxymethyl chitosan and sodium alginate, so that the exosome is protected from being degraded in the stomach, and the activity of the exosome in the stomach is improved. The exosome can be effectively released under the intestinal pH and flora environment, so that the targeted delivery of the intestinal tract is realized, and the preparation method is suitable for improving the intestinal inflammation and maintaining the intestinal health. The invention can effectively solve the technical problems of uncontrollable raw material quality and safety, low oral delivery stability and active ingredient availability and poor medication compliance of the existing plant exosome.

The present invention pertains to a liposome comprising cannabidiol (CBD), a phospholipid component and optionally a sterol component, wherein the liposome comprises more than one bilayer, to related mixtures of liposomes, processes for manufacturing,medicalusesandcompositions.

The invention provides a glabridin flexible liposome, a glabridin flexible liposome mask liquid and a preparation method, and relates to the technical field of cosmetics. The glabridin flexible liposome provided by the invention comprises a flexible nano liposome and glabridin wrapped by the flexible nano liposome, the flexible nano liposome is a liposome modified by dipotassium glycyrrhizinate, and the liposome is formed by phospholipid and cholesterol. According to the invention, the dipotassium glycyrrhizinate is used as an edge active agent, and the glabridin is wrapped in the flexible liposome, so that the problems of poor solubility and poor stability of the glabridin are solved while the transdermal properties of the glabridin and the dipotassium glycyrrhizinate are improved. According to the glabridin flexible lipidosome mask liquid provided by the invention, the glabridin flexible lipidosome is uniformly dispersed in the mask liquid, and the obtained glabridin flexible lipidosome mask liquid has excellent stability and also has good moisturizing, soothing and whitening effects.

The invention discloses a composite embedded vitamin liposome as well as a preparation method and application thereof, by optimizing a formula and a process, adopting high-purity natural plant source phospholipid, a proper amount of a wall material and a membrane stabilizer and combining an antioxidant, the vitamin retention rate exceeds 95% after the liposome is accelerated at 60 DEG C for 20 days, and the rehydration particle size is between 200 and 800nm; the flowability is good, no bad taste or smell exists, and efficient embedding and stable release of vitamins are realized. The liposome has excellent physical and chemical stability and is suitable for various dosage forms such as tablets and hard-shell capsules, and the bioavailability and market application value of the product are remarkably improved. In addition, a clean solvent ethanol is used in the preparation process and is effectively removed and recycled, so that the method meets the requirements of food processing industry laws and regulations, is environment-friendly and is suitable for large-scale production.

The invention discloses a composition containing a polypeptide exosome and application of the composition in preparation of a product with skin repair ability, and particularly relates to the technical field of biology, the composition comprises polypeptide-exosome composite nanoparticles, and a polypeptide containing a GRGDS motif and an umbilical cord Wharton's jelly exosome are covalently crosslinked; the lipid double-layer coating layer comprises phosphatidylcholine, cholesterol and PEG-2000, and the molar ratio of the phosphatidylcholine to the cholesterol to the PEG-2000 is 5: 3: 2; the synergist is prepared from 0.1 to 5 percent of epicatechin gallate and 2 to 8 percent of recombinant collagen III oligopeptide. The nano-liposome is prepared through microfluidic self-assembly and a film hydration-ultrasonic intercalation method, and can be loaded on a degradable microneedle patch, so that targeted slow release of a wound part is realized. Through the synergistic effect of targeted delivery, oxidation resistance and collagen regeneration, the skin repair efficiency is remarkably improved, and the healing time is shortened.

The present invention relates to compositions for in vitro and in vivo delivery of nucleic acids, in particular messenger RNAs (mRNAs), into a target cell and their applications. The present invention is directed to a composition comprising (A) at least one nucleic acid and (B) at least one lipid nanoparticle (LNP) comprising (i) at least one ionizable lipid; (ii) at least one phospholipid; (iii) at least one sterol, especially neutral sterol; (iv) at least one poly(ethyleneglycol)-lipid (PEG-lipid); and (v) an imidazolium-based cationic lipid of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9, Y and A− are as defined in the description. The present invention also relates to a method for in vitro or in vivo transfection of live cells and uses of said composition.

The invention discloses a QS-21 composite adjuvant and a preparation method thereof, and belongs to the technical field of biological medicines. According to the QS-21 composite adjuvant, a polyanion material and QS-21 are compounded to form nanoparticles, and the nanoparticles are organically combined with a freeze-drying protective additive, so that the prepared QS-21 composite adjuvant is relatively high in retention rate, the problems of hydrolysis and oxidation are solved, the requirement of a phospholipid carrier is avoided, and a vaccine co-preparation process is simplified; the subsequently added freeze-drying protective agent retains the immune enhancement activity of the QS-21 and reduces the exposure of the QS-21 to a degradation environment; the corresponding cytotoxicity meets the standard, and the hemolysis rate is low; therefore, the method has remarkable clinical application value and industrialization potential.

The invention provides an engineered bacterium outer vesicle drug delivery system capable of efficiently penetrating a blood brain barrier and targeting glioblastoma as well as a preparation method and application of the engineered bacterium outer vesicle drug delivery system, and belongs to the field of drug delivery. The engineering bacteria outer vesicle drug delivery system comprises double-layer phospholipid layer vesicles BEVs, a drug delivery system and a drug delivery system, wherein the particle size of the double-layer phospholipid layer vesicles BEVs is 20 The anti-tumor drug is wrapped in the BEVs, the surface of the BEVs is modified with functional polypeptide, and the functional polypeptide is at least one of Angiopep-2 and TAT cell penetrating peptide. Animal experiments verify that the synergistic effect of the Angiopep-2 and the TAT peptide can overcome the problem of modification saturation of the Angiopep-2 peptide, and significantly improve the ability of BEVs to penetrate through BBB and target tumor tissues. Therefore, the BEVs modified by the Angiopep-2 peptide and the TAT peptide have the advantages of multi-stage targeting, high efficiency and synergy, and can effectively deliver chemotherapeutic drugs to tumor tissues.

The invention relates to the field of synthetic phospholipids, in particular to a synthetic phosphatidylcholine-like refining method which comprises the following steps: A, dissolving: adding a mixed solvent into synthetic phosphatidylcholine-like, and stirring for dissolving to obtain a crude product solution; b, complexing: adding a metal salt into the crude product solution, mixing, and continuously stirring for dissolving to obtain a primary refined solution; c, crystallization: adding an indissolvable organic solvent into the primary refined liquid, then cooling for crystallization, and carrying out solid-liquid separation to obtain solid crystals; and D, cleaning: rinsing and drying the solid crystal to obtain a refined phosphatidylcholine product. The refining method provided by the invention is green in process and low in cost, and high-purity synthetic phosphatidylcholine with the purity of 98% or above is obtained.

The invention relates to the technical field of detection kits, in particular to a blood coagulation reaction linked lupus anticoagulant fluorescence detection kit and application thereof, the kit contains a screening-confirmation integrated reagent, a calibration product, a quality control product and an anticoagulation interference inhibitor; the integrated reagent is divided into a reagent A and a reagent B, the reagent A contains a buffer solution, recombinant snake venom thrombin, composite phospholipid, a fluorescent substrate and other components, and the reagent B contains prothrombin, calcium ions, high-concentration composite phospholipid and other components; the composite phospholipid system is formed according to a specific proportion and modifies beta2-glycoprotein I, the fluorescence enhancement-stabilization system is formed by matching a Schiff base compound with a stabilizer, the calibrator is a series of lupus anticoagulant standard substances, and the quality control substance comprises simulants with different concentrations and negative control. The anti-interference capability is high, and the influence of anti-coagulant drugs and enzyme source fluctuation is reduced; the signal amplification effect is obvious, the detection sensitivity is high and the reagent stability is good; the operation is simple and convenient, screening and confirmation are integrally completed, and a conventional fluorescence detector is adapted.